XPose Therapeutics establishes collaboration with Naaz Coker Ovarian Cancer Research Centre (NOVARC) at the University of Nottingham within the Biodiscovery Institute, to work on multiple DDR pipeline targets including POLH, APE1, FEN1 and PARP1.

XPose Therapeutics will participate in BIO 2023, Boston, sponsored by the National Cancer Institute.

XPose Therapeutics will participate in BIO Partnering at the 41st Annual J. P. Morgan Healthcare Conference, San Francisco.

Poster at the American Chemical Society Fall Meeting, Chicago, on "Exploring the DRome ("DNA repair-ome".

Poster at the 5th DNA Repair/Replication Structures and Cancer Conference, Cancun, on "Towards new DDR therapeutics by fragment-based drug discovery".

Talk at the 5th Annual DDR, ATR & PARP Inhibitors Summit, Boston, on "Quick SAR by X-ray Poses".

XPose Therapeutics participates in BIO Partnering at the 40th Annual J. P. Morgan Healthcare Conference.

Poster at the Mammalian DNA Repair Gordon Research Conference on Understanding and Targeting the DNA Repair Pathways on "Targeting APE1 for novel cancer therapeutics".

Talk at the 4th Targeted Protein Degradation Summit on "Discovery and development of targeted protein degraders for DDR therapeutics by screening compound libraries to obtain empirical 3D information".

Abstract at the ASCO (American Society of Clinical Oncology) 2021 Annual Meeting on our “Development of a DNA damage response (DDR) therapeutics platform for oncology".

​

Read the abstract here.

Poster on "Targeting the DNA repair enzyme APE1 in cancer therapy" presented at "The 1st International Electronic Conference on Cancers: Exploiting Cancer Vulnerability by Targeting the DNA Damage Response".

​

Read the presentation here.

XPose Therapeutics and Accelero Biostructures announce Joint Research Collaboration for the Discovery and Development of Novel Cancer Therapies.

​

Read the article here.

Publication on our DDR/cancer therapeutics efforts "Fragment- and structure-based drug discovery for developing therapeutic agents targeting the DNA Damage Response" 

​

Read the article here.

XPose Therapeutics is very excited to receive non-dilutive funding (SBIR Phase I) from the National Cancer Institute of the National Institutes of Health to advance the discovery and development of novel therapeutics targeting DDR in cancer.

​

Full announcement here.

XPose Therapeutics accepted into Spring 2020 session of Berkeley SkyDeck HotDesk (Incubator) program.

XPose Therapeutics licences hits from Accelero Biostructures for launching focused therapeutics development for DDR target APE1.

XPose Therapeutics ("X-ray Poses" or "XPose") receives support for launch from University of California's QB3.